1612 GMT - Philips's cautious outlook for this year doesn't surprise after the company posted only slight order intake growth in 2024, ING analysts say in a note. The Dutch medical-device company's order intake grew 2% in the fourth quarter, bringing the annual growth rate to 1%, they say. With that in mind, it's unsurprising that the guidance for 1%-3% organic growth, including continued decline in China in 2025, was also a little weaker than expected, the analysts say. Divisionally, Philips posted a large adjusted Ebita shortfall in its core Diagnosis & Treatment division, offset by better-than-expected results in Connected Care, as the unit is recovering from its Respironics sleep apnea machines recall. Shares are down 12% at 23.81 euros.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 19, 2025 11:12 ET (16:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。